Income statement
USD
Annual
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Revenue | 3M | 1M | 0 | 0 | 0 |
| Gross Profit | 3M | 1M | -628K | -430K | -205K |
| Operating Income | -6M | -9M | -11M | -8M | -5M |
| EBITDA | -5M | -8M | -11M | -8M | -5M |
| Net Income | -6M | -9M | -11M | -8M | -5M |
| EPS (Diluted) | — | — | — | — | — |
Healthcare
Live Price
Offline$0.003
+0.00% today
1Y Change
-90.00%
Window
Jun 23, 2025 → Jun 18, 2026
Coverage: 249 bars · Jun 23, 2025 → Jun 18, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Verici Dx plc (VRCDF) is a Healthcare stock with a market cap of $10.00M and listed on OTC. The stock last traded around $0.00 and down 90.0% across the available one-year price window (Jun 23, 2025 → Jun 18, 2026). Baseline metrics include revenue growth of +229.6%, EPS growth of +51.3%, a dividend yield of 0.0%. What stands out right now is revenue +229.6%, EPS +51.3%, free cash flow +15.9% with operating margin -472.6% and ROIC -243.2%. Valuation sits in the middle of the pack at price/sales 6.7. Overall, the current profile looks closer to a higher-growth but lower-margin setup than a generic broad-market placeholder. Stock Foundry combines VRCDF price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
VRCDF
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
VRCDF Max Drawdown
-90.00%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for VRCDF and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$0.0
FY Net Income
-$5.0M
+39.4% YoY
Free Cash Flow
-$1.1M
+85.2% YoY
Revenue Growth
+229.6%
EPS Growth
+51.3%
Gross Margin
105.8%
Net Margin
-468.3%
Income statement
USD
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Revenue | 3M | 1M | 0 | 0 | 0 |
| Gross Profit | 3M | 1M | -628K | -430K | -205K |
| Operating Income | -6M | -9M | -11M | -8M | -5M |
| EBITDA | -5M | -8M | -11M | -8M | -5M |
| Net Income | -6M | -9M | -11M | -8M | -5M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Cash & Equivalents | 4M | 3M | 10M | 10M | 18M |
| Total Assets | 7M | 7M | 14M | 14M | 20M |
| Total Liabilities | 2M | 4M | 3M | 2M | 682K |
| Shareholder Equity | 5M | 4M | 12M | 12M | 20M |
| Total Debt | 371K | 540K | 156K | 0 | 74K |
| Net Debt | -4M | -2M | -10M | -10M | -18M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
911K
+85.6% YoY
Capital Expenditures
169K
+82.6% YoY
Free Cash Flow
1M
+85.2% YoY
Key ratios
Gross Margin
105.8%
Operating Margin
-472.6%
Net Margin
-468.3%
ROE
-178.4%
Debt / Equity
0.11x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.